TODD STRATEGY GROUP

Lobbying for BRISTOL-MYERS SQUIBB COMPANY · Biopharmaceutical company.

Filing 1st Quarter - Report

1st Quarter (Jan 1 - Mar 31) 2025 · District of Columbia · House · Senate · $50,000.00 income · posted Apr 21, 2025

Lobbying activity 2

Medicare/Medicaid

Biosimilars reimbursement issues. Supply Chain Issues. Pharmacy Benefit Manager Reform.

Health Issues

Medicare/Medicaid payment reform. Implementation of Inflation Reduction Act of 2022. 340B Program

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.